Piper Sandler maintains ICU Medical at Overweight, raises price target to $200 from $195

Piper Sandler kept ICU Medical at Overweight, raising its price target to $200 from $195, suggesting a 19.3% upside from the Nov 5 close of $167.65.

Original reporting
Published Nov 6, 2026, 2:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Piper Sandler maintains ICU Medical at Overweight, raises price target to $200 from $195 — source image
Decision brief

The 30-second read

$ICUBullishMed
01

Why it matters

The upgrade to Overweight and higher target may attract new buying interest.

02

Market read

A fresh analyst upgrade can prompt immediate buying, offering a short-term trade idea.

03

What to watch

Potential supply chain constraints not addressed in the note.

Relevance 7/10Novelty 6/10Timing: today

Background

Analyst rating updates are common catalysts for short-term price moves.

Company-level read

Ticker impact

$ICUBullishHigh confidence
Context

Piper Sandler raised its price target for ICU Medical to $200, indicating a fresh bullish view.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Target increase from $195 to $200 signals improved expectations, prompting buying interest.

Market effects

May lift sentiment for the medical device sector.

Limited to US markets where ICU trades.

Low

Counterpoint

Target raise could be premature if upcoming earnings miss expectations.

Key entities

  • Piper Sandler

    Equity research firm issuing the rating change.

  • ICU Medical

    Medical device manufacturer whose stock is the subject.

Related articles

$ICUHigh

SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates

SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025 Achieved nearly 75% enrollment in the NEUTRALIZE-AKI p